A case of acquired rifampin resistance in Mycobacterium bovis bacillus Calmette-Guérin-induced cystitis: Necessity for treatment guidelines

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 17, Issue 3, 2006, Pages 183-185

  Wolfe, Joyce N ^a,e   Blackwood Antonation, Kym S ^a   Sharma, Meenu K ^a,b   Cook, Victoria J ^c,d  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Canadian Science Centre for Human and Animal Health   (Canada)

Author keywords

BCG; Rifampin resistance; rpoB

Indexed keywords

ALLOPURINOL; AMINOSALICYLIC ACID; BCG VACCINE; CAPREOMYCIN; DILTIAZEM; ETHAMBUTOL; ETHIONAMIDE; ETIDRONIC ACID; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; CYSTITIS; CYSTOSCOPY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; HUMAN; MYCOBACTERIUM BOVIS; PRACTICE GUIDELINE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 33746865529     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/263932     Document Type: Article

References (14)

1. Kim BJ, Lee SH, Lyu MA, et al. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB). J Clin Microbiol 1999;37:1714-20.
2. Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: A blind study at reference laboratory level. J Clin Microbiol 1997;35:719-23.
3. Aljada IS, Crane JK, Corriere N, Wagle DG, Amsterdam D. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol 1999;37:2106-8.
4. Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Supp 13):S86-S90.
5. Lamm D. Optimal treatment of superficial bladder cancer in 1994. Can J Urol 1995;2(Supp 1):1-6.
6. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
7. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer (Cochrane Review). In: The Cochrane Library, Oxford: Update Software, 2001.
8. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36:140-8.
9. Hesseling AC, Schaaf HS, Victor T, et al. Resistant Mycobacterium bovis Bacillus Calmette-Guerin disease: Implications for management of Bacillus Calmette-Guerin Disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004;23:476-9.
10. Sicevic S. Generalized BCG tuberculosis with fatal course in two sisters. Acta Paediatr Scand 1972;61:178-84.
11. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:662-7.
12. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992;19:565-72.
13. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001;2:164-8.
14. Heep M, Brandstatter B, Rieger U, et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001;39:107-10.